The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | ALINA: evaluating the safety of adjuvant alectinib for ALK+ NSCLC
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses the safety outcomes of the Phase III ALINA trial (NCT03456076) of adjuvant alectinib versus chemotherapy in resected stage IB-IIIA ALK-positive non-small cell lung cancer (NSCLC). Alectinib demonstrated significant disease-free survival benefits, and common adverse events (AEs) such as increased blood creatine phosphokinase (CPK), constipation, and elevated liver enzymes were reported. Most AEs were mild, manageable, and rarely required dose modifications. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
